Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 2/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831290 | 0.86 | MME (0.61) | KMT2AKCNQ2MAPTMMEALDH1A1 | |
| SCHEMBL9831283 | 0.86 | MME (0.61) | KMT2AKCNQ2MAPTMMEALDH1A1 | |
| SCHEMBL1449796 | 0.85 | KCNQ2 (0.55) | KMT2AKCNQ2MAPTMMEALDH1A1 | |
| SCHEMBL9828894 | 0.83 | MME (0.63) | KMT2AKCNQ2MAPTMMEALDH1A1 | |
| SCHEMBL9828899 | 0.83 | MME (0.63) | KMT2AKCNQ2MAPTMMEALDH1A1 | |
| SCHEMBL5283204 | 0.83 | KMT2A (0.56) | KMT2AMMEMMP2MMP9NAALAD2 | |
| SCHEMBL2330908 | 0.81 | LTA4H (0.54) | KCNQ2MAPTALDH1A1 | |
| SCHEMBL2330911 | 0.81 | LTA4H (0.54) | KCNQ2MAPTALDH1A1 | |
| SCHEMBL6426081 | 0.81 | KMT2A (0.56) | KMT2AMMEMMP2MMP9NAALAD2 | |
| SCHEMBL2330325 | 0.80 | MME (0.49) | KMT2AKCNQ2MAPTMMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005053607-A2 | METHOD FOR PREVENTING HEPATIC ENCEPHALOPATHIC EPISODES | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2005-06-16 | — | — | WO | claimed |
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | MEDICIS PHARMACEUTICAL CORPORATION | 2004-11-18 | — | — | US | claimed |
| US-20240041807-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2024-02-08 | — | — | US | disclosed |
| US-11819483-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230181504-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2023-06-15 | — | — | US | disclosed |
| US-11517547-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200170984-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2020-06-04 | — | — | US | disclosed |
| EP-3645053-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | Baylor College of Medicine (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10183006-B2 | Methods of therapeutic monitoring of nitrogen scavenging drugs | HORIZON THERAPEUTICS, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2019006164-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3133396-B1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20110079093-A1 | Methods of Distinguishing Between Glutamine Formed by Cataplerosis or Proteolysis | BIOCANT (PT) | 2011-04-07 | — | — | US | disclosed |
| EP-2286238-A1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | Biocant - Associação De Transferência De Tecnologia (PT) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010025303-A9 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010025303-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2009141619-A1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | Biocant - Associação De Transferência De Tecnologia (PT) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009134460-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2005053607-A2 | METHOD FOR PREVENTING HEPATIC ENCEPHALOPATHIC EPISODES | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | MEDICIS PHARMACEUTICAL CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | OAT, PYGL, SLC10A1 | KMT2A 3686/4885KCNQ2 3478/4885MAPT 243/4885 |
| US-10183006-B2 | Methods of therapeutic monitoring of nitrogen scavenging drugs | OAT, NPR1, CPS1 | KMT2A 3883/4885KCNQ2 3943/4885MAPT 3758/4885 |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | OAT, SLC1A5, GLS | KMT2A 1446/4885KCNQ2 3684/4885MAPT 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.